Another study found that the success rate of anti-PD-1/PD-L1 therapy in patients with renal cell carcinoma (RCC) or uroepithelial carcinoma (UC) was positively correlated with the diversity of the patient’s gut microbiota (Routy et al., 2018). The gene discussed is CD274; the disease is renal cell carcinoma.